Equillium (EQ) Projected to Post Quarterly Earnings on Thursday

Equillium (NASDAQ:EQ) is expected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.05) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ) last announced its earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, analysts expect Equillium to post ($0.21) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.

Equillium Stock Performance

Equillium stock opened at $1.40 on Thursday. The stock has a fifty day moving average of $1.72 and a two-hundred day moving average of $2.07. The company has a market capitalization of $88.77 million, a price-to-earnings ratio of -7.00 and a beta of 2.08. Equillium has a fifty-two week low of $0.76 and a fifty-two week high of $3.54.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Roth Capital restated a “buy” rating on shares of Equillium in a research report on Monday, October 26th. Wall Street Zen downgraded shares of Equillium from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Piper Sandler started coverage on shares of Equillium in a report on Monday, July 13th. They issued an “overweight” rating on the stock. Zacks Research raised shares of Equillium from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Leerink Partners began coverage on shares of Equillium in a research note on Monday, October 12th. They set an “outperform” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Equillium has an average rating of “Moderate Buy” and a consensus target price of $7.57.

About Equillium

Equillium, Inc is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company seeks to address immune-system dysregulation by developing treatments that selectively modulate immune-cell activity rather than broadly suppressing the immune system.

Equillium’s lead product candidate is itolizumab, a monoclonal antibody that targets CD6, a protein involved in the activation and trafficking of certain T cells. The company has evaluated itolizumab in conditions including acute graft-versus-host disease and lupus nephritis.